Purpose: To evaluate the safety and efficacy of prostate artery embolization (PAE) for the treatment of benign prostatic hyperplasia for prostates ≥ 80 mL. Patients and Methods: A retrospective review was conducted of 93 patients with prostate volumes (PVs) ≥ 80 mL treated with PAE from April 2014 through October 2017. Mean patient age was 68.5 years (range 52–88) and mean age-adjusted Charlson comorbidity index was 3.2 (range 1–8). Exclusion criteria included history of biopsy-proven prostate cancer or catheter dependency. Clinical and urodynamic outcomes were reviewed at 1, 3, 6, and 12 months. Adverse events were graded according to the Clavien-Dindo classification. Results: Mean PV decreased significantly from 141.7 mL to 98.1 mL at 3 months (P <.01) and 82.2 mL at 12 months (P <.01). Significant improvements were seen in 3- and 12-month mean International Prostate Symptom Scores (IPSS) (22.3 vs 7.1 and 7.3, respectively; P <.01 for both), quality of life (QOL) (4.4 vs 1.2 and 1.3; P <.01 for both), and postvoid residual volume (196.7mL vs 92.1 and 61.2 mL; P <.01 and P <.01, respectively). Significant improvement was also seen in 3-month mean maximum urinary flow: 7.7 mL/s vs 12.8 mL/s (P <.01). One grade II complication of stroke occurred; all other complications were self-limited and grade I. Conclusions: PAE achieved a clinically and statistically significant improvement in symptom burden and secondary outcome measures in patients with PVs ≥ 80 mL. PAE may be an alternate treatment for patients for whom conventional surgical options are limited or associated with significant morbidity.
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Cardiology and Cardiovascular Medicine